CB-103 for Osteosarcoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Osteosarcoma+7 MoreCB-103 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, CB-103, to see if it is safe and effective. So far, it seems to be working well.

Eligible Conditions
  • Osteosarcoma
  • Glomangiosarcoma
  • Non-Hodgkin Lymphoma
  • Colorectal Cancer
  • T-Cell Acute Lymphoblastic Leukemia
  • Adenoid Cystic Carcinoma
  • Liver Cancer
  • Breast Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: up to 12 months

28 days
Part A: Dose limiting toxicity (DLT)
Day 28
Part A and B: pharmacokinetic - AUC
Part A and B: pharmacokinetic - Cmax
Part A and B: pharmacokinetic - t1/2
Part A and B: pharmacokinetic - tmax
up to 12 months
Part A and B: incidence of all adverse events and serious adverse events (safety and tolerability)
Part B: antitumour efficacy
up to 6 months
Part A: preliminary antitumour efficacy

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

CB-103
1 of 1

Experimental Treatment

200 Total Participants · 1 Treatment Group

Primary Treatment: CB-103 · No Placebo Group · Phase 1 & 2

CB-103
Drug
Experimental Group · 1 Intervention: CB-103 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 12 months

Who is running the clinical trial?

Cellestia Biotech AGLead Sponsor
1 Previous Clinical Trials
80 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients with histologically or cytologically confirmed solid tumours (breast cancer (triple negative breast cancer [TNBC], ER+/-, HER2+/-), gastrointestinal (GI) cancers (resistant to oxaliplatin or irinotecan-based therapy colorectal cancer [CRC]), osteosarcoma, adenoid cystic carcinoma (ACC), and malignant glomus tumour) that are surgically unresectable, locally advanced, or metastatic and whose disease has progressed on at least one line of systemic therapy (with the exception of ACC patients who are allowed to be systemic treatment-naïve) are eligible for this study
You have a disease.\n
, by sex The table shows the number of men and women aged 18 or older, by sex.
are necessary for a successful transplant
People with T-cell acute lymphoblastic leukaemia (T-ALL) or lymphoma (T-LBL) who have a confirmed NOTCH pathway activation and have not achieved a CR after standard induction/consolidation therapy attempt are defined as refractory patients.